Rituximab (a humanized anti-CD20 monoclonal antibody) is a useful treatment for Epstein-Barr virus-associated post transplant lymphoproliferative disease (EBV-PTLD). However, hypogammaglobulinemia is a complication associated with this treatment. 1, 2 Little is known about the duration and severity of rituximab-induced low serum immunoglobulin (Ig) status. Recently, Castagnola et al 3 reported a patient with severe hypogammaglobulinemia that persisted for more than 2 years (27 months þ ) after rituximab infusion for pre-emptive therapy for EBV-PTLD. One of three patients reported by Verschuuren et al 1 died of invasive aspergillosis due to hypogammaglobulinemia after 7 months of rituximab treatment.
We describe here our experience with a 20-year-old man who was treated with rituximab for high-risk EBV-PTLD following bone marrow transplantation (BMT) for acquired aplastic anemia. The patient received two courses of rituximab (375 mg/m 2 /weekly Â 8 doses for each course) in April-May and in October-November 2000. The patient recovered remarkably after the treatment, with steadily regressed LPD masses, as described in detail in our previous publication. 4 Since then, the patient has had hypogammaglobulinemia for more than 2.5 years despite continuous replacement therapy with intravenous Ig (IVIG) as high-titer anti-CMV-gammaglobulin, partly because of his history of cytomegalovirus retinitis ( Figure 1 ). Before allogeneic BMT performed on October 27, 1998, the patient had normal serum Ig levels: IgG 1131 (normal 870-1700) mg/dl, IgA 165 (normal 110-410) mg/dl and IgM 129 (normal 33-190) mg/dl. At 8 months after BMT, his serum IgG levels remained above 1000 mg/dl due to the post transplant Ig replacement therapy.
Completion of the replacement therapy combined with continuous administration of cyclosporin A (CSA) for the control of limited chronic GVHD resulted in low serum Ig levels: IgG 431, IgA and IgM 7 mg/dl just before the rituximab treatment. After the first course of rituximab (Figure 1 ), serum Ig levels declined to their lowest levels: IgG 318, IgA 7 and IgM 3 mg/dl. In response to the replacement therapy (intravenous immunoglobulin, 10 g per 4 weeks) initiated soon after the second course of rituximab (Figure 1 ), serum IgG levels have remained at 550-650 mg/dl, however, IgA and IgM levels remained below 10 mg/dl. Serum levels of IgD (o1.0 mg/dl, normal o11.5) and IgE (3 mg/dl, normal o300) were also very low. Over the past 2 years, repeat analysis of peripheral blood mononuclear cells revealed that T(CD2 þ )-cell numbers ranged from 660 to 998/ml (normal 605-2564) and B(CD20 þ )-cell numbers ranged from 6 to 132/ml (normal 70-663). The CD4 þ T-cell subset was in the range of 228-382/ml and the CD8 þ T-cell subset ranged from 337 to 519/ml, with a CD4/CD8 ratio of 0.61-0.83. Although spontaneous recovery of Ig production has not yet occurred as of May 2003, slow immune reconstruction is expected due to the steady increase in B-cells that are doubling approximately every 9 months (Figure 1) . Treatment with rituximab for EBV-PTLD (as opposed to treatment for autoimmune hemolytic anemia 2 ) appears to cause more severe and prolonged B-cell deficiency and hypogammaglobulinemia.
5-7 However, extremely long-lasting B-cell deficiency like our case may be rare. 3 In the report of van Esser et al, 6 B lymphopenia recovered between 6 and 9 months after a single infusion of rituximab as a pre-emptive therapy. In addition, in the control of PTLD, one to nine infusions were shown to be effective. 5, 7 Our case might be exceptional, because he needed two courses (a total of 16 infusions) because of very refractory multiple LPD masses in the adrenal glands, lungs, kidneys, liver and para-aortic lymph nodes as well as no availability of donor-derived EBV-specific CTLs at the time. 4 It is possible that this intensive treatment might be responsible for such prolonged B-cell deficiency in our patient, but in the case of Castagnola et al, 3 only a single dose was administered. A correlation between the duration of B lymphopenia and numbers (doses) of rituximab administered needs to be analyzed in future studies.
Although our patient has had hypogammaglobulinemia for more than 2.5 years, he has not had infectious complications and the cytomegalovirus retinitis remains stable, indicating the effectiveness of continuous IVIG replacement therapy. Currently, the patient is doing well, with a Karnofsky score of 100%. Every EBV-PTLD patient treated with rituximab must be monitored closely with regard to serum Ig levels as well as peripheral B-cell numbers. IVIG replacement therapy is essential when IgG levels fall below 500 mg/dl, and therapy may be necessary for more than 2 years in severely affected patients to prevent hypogammaglobulinemia-related life-threatening infectious complications. 
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